Genentech: Tarceva plus Avastin stalls lung cancer progression

02/3/2009 | Reuters

Genentech reported interim findings from a late-stage study showing that the combination of its drugs Avastin and Tarceva significantly prolonged survival in people with nonsmall-cell lung cancer without disease progression. The results prompted Genentech to halt the trial, indicating that the combination's "clinical benefit is likely quite significant," an analyst said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN